Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
XENE Xenon Pharmaceuticals
39.190+0.850+2.22%
Close
02/03 16:00 ET
39.1900.0000.00%
Post Mkt Price 02/03 16:01 ET
High
39.490
Open
38.140
Turnover
8.10M
Low
37.910
Pre Close
38.340
Volume
207.57K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Royal Bank of Canada Raises Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $51.00
Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) had its price objective hoisted by equities researchers at Royal Bank of Canada from $49.00 to $51.00 in a research report issued on Tuesday, Benzing
RBC Lifts Price Target on Xenon Pharmaceuticals to $51 From $49 Amid Increased Confidence on Patents, Keeps Outperform Rating, Speculative Risk Qualifier
08:01 AM EST, 01/31/2023 (MT Newswires) -- Xenon Pharmaceuticals (XENE) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $44 to $60.
Xenon Pharmaceuticals Price Target Raised to $51.00/Share From $49.00 by RBC Capital
Xenon Pharmaceuticals Price Target Raised to $51.00/Share From $49.00 by RBC Capital
Xenon Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/31/2023 34.21% RBC Capital $49 → $51 Maintains Outperform 12/14/2022 57.89% Goldman Sachs → $60 Initiat
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $51
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals with a Outperform and raises the price target from $49 to $51.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of "Moderate Buy" From Analysts
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) has received an average recommendation of "Moderate Buy" from the fourteen brokerages that are covering the company, MarketBeat.com reports. One
Is Pharma M&A Making a Comeback?
Jaimy Lee A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies A handful of acquisitions this week point to a more deal-friendly year for biopha
Will 2023 Be the Year That Pharma M&A Makes a Comeback?
Jaimy Lee A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies A handful of acquisitions this week point to a more deal-friendly year for biopha
Handelsbanken Fonder AB Has $383,000 Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Handelsbanken Fonder AB decreased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) by 30.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities
Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) saw unusually large options trading on Wednesday. Stock investors bought 4,063 put options on the company. This represents an increase of approx
Company Overview
More
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
CEO： Mr. Ian C. Mortimer
Market： NASDAQ
Listing Date： 11/05/2014
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet